What type of study is this?

This is a In Vitro Study study.

December 8, 2025BloodOpen Access

The m5C-binding protein YB-1 modulates proteasome inhibitors resistance in multiple myeloma via epigenetic modification

View Full Paper

Ask AI

Bookmark

Authors

Experimental analysis demonstrates that YB-1 modulates apoptosis and chemoresistance in multiple myeloma through RNA 5-methylcytosine changes.

YB-1 modulates apoptosis and protects multiple myeloma cells from proteasome inhibitors.
In vitro testing showed that YB-1 knockdown significantly enhances apoptosis in multiple myeloma cells.
The analysis employed high-throughput sequencing to identify pathways linked to YB-1's function.
These findings highlight the critical role of RNA modifications in cancer therapy resistance.

Zhen Cai (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Experimental analysis demonstrates that YB-1 modulates apoptosis and chemoresistance in multiple myeloma through RNA 5-methylcytosine changes.

YB-1 modulates apoptosis and protects multiple myeloma cells from proteasome inhibitors.
In vitro testing showed that YB-1 knockdown significantly enhances apoptosis in multiple myeloma cells.
The analysis employed high-throughput sequencing to identify pathways linked to YB-1's function.
These findings highlight the critical role of RNA modifications in cancer therapy resistance.

Zhen Cai (2025) studied this question.

View Full Paper

Ask AI

Bookmark